BIORCHESTRA - About the company
BIORCHESTRA is a series C company based in Yuseong District (South Korea), founded in 2016 by JH Ryu Branden. It operates as a Developer of RNA based medicines for treating neurodegnerative disease. BIORCHESTRA has raised $45M in funding from investors like Chong Kun Dang Pharmaceutical, SBI Mutual Fund and Smile Gate Investment. The company has 457 active competitors, including 161 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.
Company Details
Biorchestra develops RNA-based medicines for treating neurodegenerative diseases. The company is developing an RNA sequence and RNA delivery technology that delivers mRNA or microRNA regulators to the cytoplasm. The pipelined products are for Alzheimer's and amyotrophic lateral sclerosis.
- Website
- biorchestra.com
- Email ID
- *****@biorchestra.com
- Phone Number
- +82 **********
Key Metrics
Founded Year
2016
Location
Yuseong District, South Korea
Stage
Series C
Total Funding
$45M in 1 round
Latest Funding Round
Investors
Ranked
142nd among 457 active competitors
Employee Count
16 as on Jun 30, 2026
Similar Companies
Legal entities associated with BIORCHESTRA
BIORCHESTRA is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
BIORCHESTRA US, INC. CIN: 873116249 , United States, Active | Dec 31, 1999 | - | 4 (As on Dec 31, 2023) | - |
Bio Orchestra Co., Ltd. CIN: 276-88-00551 , South Korea, Active | Oct 12, 2016 | - | - | - |
Sign up to download BIORCHESTRA's company profile
BIORCHESTRA's funding and investors
BIORCHESTRA has raised a total funding of $45M over 1 round. Its latest funding round was a Series C round on Feb 22, 2022 for $*****. 13 investors participated in its latest round. BIORCHESTRA has 16 institutional investors.
Here is the list of recent funding rounds of BIORCHESTRA:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 22, 2022 | 2578058 | Series C | 2597757 | 2896377 | 7981655 | 6177775 |
Access funding benchmarks and valuations. Sign up today!View details of BIORCHESTRA's funding rounds and investors
BIORCHESTRA's founders and board of directors
Founder? Claim ProfileThe founders of BIORCHESTRA is JH Ryu Branden. JH Ryu Branden is the CEO of BIORCHESTRA.
Here are the details of BIORCHESTRA's key team members:
- JH Ryu Branden: Founder & CEO of BIORCHESTRA.
View details of BIORCHESTRA's Founder profiles and Board Members
BIORCHESTRA's employee count trend
BIORCHESTRA has 16 employees as of Jun 26. Here is BIORCHESTRA's employee count trend over the years:
Uncover BIORCHESTRA's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
BIORCHESTRA's Competitors and alternates
Top competitors of BIORCHESTRA include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of BIORCHESTRA, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 71/100 | |
3rd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 65/100 | |
6th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
7th | Alchemab 2019, London (United Kingdom), Series A | Developer of antibody therapeutics for treating oncology and neurodegenerative conditions | $149M | 65/100 | |
8th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Developer of small molecule inhibitors targeting specific disease associated enzymes | $192M | 64/100 | |
9th |  D&D Pharmatech 2014, Seongnam-si (South Korea), Public | Developer of GLP-1-based therapeutics for metabolic disease treatment | $205M | 64/100 | |
10th | US World Meds 2001, Louisville (United States), Series B | Developer of therapeutics for the treatment of multiple diseases | $149M | 63/100 | |
142nd |  BIORCHESTRA 2016, Yuseong District (South Korea), Series C | Developer of RNA based medicines for treating neurodegnerative disease | $45M | 41/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on BIORCHESTRA's competitors? Click here to see the top ones
BIORCHESTRA's Investments and acquisitions
BIORCHESTRA has made no investments or acquisitions yet.
Reports related to BIORCHESTRA
Here is the latest report on BIORCHESTRA's sector:
News related to BIORCHESTRA
•
Biorchestra Announces Significant Progress In Studies Of Bmd-001 Drug ProgramPR Newswire•Apr 24, 2023•BIORCHESTRA
•
•
S.Korea's Biorchestra signs tech transfer deal for drug delivery systemKedglobal•Mar 28, 2023•BIORCHESTRA
•
•
BIORCHESTRA Announces BMD-001 Data at RNA Leaders USA Conference in BostonPR Newswire•Nov 09, 2022•BIORCHESTRA
•
Biorchestra Raises 45M in Series C FundingFinSMEs•Feb 28, 2022•BIORCHESTRA, Daily Partners, IMM Investment, SBI Mutual Fund and 9 others
•
Korean firms to develop new compounds for potential anti-seizure medicationBioSpectrum Asia•Jan 05, 2022•BIORCHESTRA, SK biopharmaceuticals
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about BIORCHESTRA
Explore our recently published companies
- Alfresco - London based, 1996 founded, Unfunded company
- Katana Sports - 2022 founded, Unfunded company
- Anand Rathi - Mumbai based, 1994 founded, Public company
- Providence Health & Services - United States based, 1859 founded, Funding Raised company
- Entekhaabco - Kuwait City based, 2019 founded, Unfunded company
- Glovnetics - Gurugram based, 2022 founded, Unfunded company
